Altamira Therapeutics Ltd.
CYTOF
$0.0999
-$0.01-9.10%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.34M | -5.14M | -5.94M | -15.03M | -24.96M |
| Total Depreciation and Amortization | 60.80K | 63.10K | 65.40K | 96.60K | 127.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 641.80K | 866.90K | 1.09M | 7.48M | 14.77M |
| Change in Net Operating Assets | 433.40K | -1.61M | -3.64M | -2.61M | -1.59M |
| Cash from Operations | -3.20M | -5.82M | -8.43M | -10.07M | -11.66M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 200.00 | 100.00 | -- | -- | -- |
| Other Investing Activities | 600.00 | 400.00 | 200.00 | -323.00K | -634.20K |
| Cash from Investing | 600.00 | 400.00 | 200.00 | -323.00K | -634.20K |
| Total Debt Issued | -- | 1.37M | 2.74M | 3.27M | 3.79M |
| Total Debt Repaid | -73.00K | -122.60K | -172.20K | -201.00K | -229.80K |
| Issuance of Common Stock | 2.64M | 4.33M | 6.03M | 7.20M | 8.37M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -56.40K | -119.10K | -181.80K | -205.10K | -228.40K |
| Cash from Financing | 2.51M | 5.46M | 8.41M | 10.15M | 11.84M |
| Foreign Exchange rate Adjustments | 20.20K | 38.40K | 56.60K | 87.90K | 119.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -668.20K | -314.70K | 38.80K | -149.90K | -333.30K |